Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized, double-blind trial of BLU-5937 in refractory chronic cough
2020-004136-17Phase 2Completed
- Sponsor
- BELLUS Health Inc.
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in refractory chronic cough (RCC) and chronic cough comparing BLU-5937 with Placebo (2 arms). Primary endpoint: Change from baseline to Day 28 in 24-hour cough frequency. Started Dec 2020; status: completed.
02
Drugs
camlipixant
03
Conditions
refractory chronic cough (RCC)chronic cough
Beyond the preview
Go deeper on 2020-004136-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004136-17.